Precision Oncology: How Biomarkers Guide Treatment

Precision oncology is an approach to cancer care that uses biomarkers and molecular testing to guide diagnosis, treatment, and monitoring. By learning more about the biology of a tumor, doctors can choose therapies that are more personalized to the individual patient.

Overview of Precision Oncology

Precision oncology is a modern approach to cancer care that looks closely at the unique features of a person’s tumor. Instead of treating all cancers of the same type in exactly the same way, doctors use laboratory testing to understand how the cancer is behaving at the molecular level. This can help them select treatments that are more closely matched to the biology of the disease.

A key part of precision oncology is the use of biomarkers. Biomarkers are measurable features in cancer cells or in the body that give information about the cancer. They may include gene mutations, changes in proteins, patterns of gene expression, or other molecular signals. Some biomarkers help confirm a diagnosis, while others help predict which treatments are more likely to work.

Precision oncology does not replace standard cancer care. Rather, it adds another layer of information to support treatment planning. Surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy, and supportive care may all still play important roles. The goal is to make treatment decisions more informed, more individualized, and better aligned with each patient’s condition.

What Are Biomarkers and Why Do They Matter?

In cancer care, biomarkers are biological clues that help doctors learn more about a tumor. Some biomarkers show what is driving cancer growth. Others suggest whether a cancer may respond to a specific medicine, whether it may be more aggressive, or how it should be monitored over time.

Biomarkers are often grouped into a few broad categories. Diagnostic biomarkers help identify a cancer type or subtype. Prognostic biomarkers give information about the likely course of disease. Predictive biomarkers help estimate whether a certain treatment may be effective. In practice, one biomarker can sometimes play more than one role.

Examples include mutations in genes such as EGFR, ALK, BRAF, or BRCA, as well as protein markers such as HER2 or PD-L1. These biomarkers are relevant in some cancers, but not in all. The same marker may also have a different meaning depending on the cancer type. That is why results should always be reviewed by specialists who understand both the test and the clinical situation.

• Some biomarkers guide the use of targeted therapies.
• Some help determine whether immunotherapy may be considered.
• Some support risk assessment, monitoring, or clinical trial selection.
• Some have value only in certain tumor types or disease stages.

How Biomarker Testing Is Done

Biomarker testing usually starts with a sample. In many cases, this is a piece of tumor tissue collected during a biopsy or surgery. A pathology laboratory examines the sample under a microscope and may perform additional tests to look for specific proteins, gene changes, or broader molecular patterns. This may include immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, or next-generation sequencing.

In some situations, testing can also be done using a blood sample. This is often called a liquid biopsy. Liquid biopsy looks for fragments of tumor DNA or other cancer-related material circulating in the blood. It may be helpful when tissue is difficult to obtain, when doctors want to monitor changes over time, or when they are looking for signs of resistance to treatment. However, it does not replace tissue testing in every case.

The type of test chosen depends on the cancer type, the stage of disease, previous treatments, and the clinical question being asked. Sometimes doctors order a single-gene test when a specific alteration is strongly suspected. In other cases, a broader panel may be more useful. Test selection is important because not all assays look for the same biomarkers, and not all results are equally actionable.

Turnaround time can vary, and waiting for results can be stressful. Patients are often reassured to know that this testing is done to improve decision-making rather than delay care unnecessarily. The cancer team balances the need for timely treatment with the value of obtaining the right molecular information.

How Biomarkers Guide Treatment Choices

One of the main benefits of precision oncology is that biomarker results can help match patients with treatments that are more likely to be useful. If a tumor has a known molecular target, doctors may recommend a medicine designed to block that target. This is the basis of targeted therapy, which aims to interfere with cancer-specific pathways rather than affecting all rapidly dividing cells in the same way.

Biomarkers can also inform the use of immunotherapy. For example, some tests help estimate whether the immune system may recognize and respond to a tumor more effectively with immune-based treatment. In some settings, doctors may also look for features such as mismatch repair deficiency or high tumor mutational burden, which can influence whether immunotherapy is considered.

At the same time, biomarker results may help avoid treatments that are less likely to work. This can reduce unnecessary side effects and support more efficient care planning. Results may also help identify eligibility for chemotherapy, combined approaches, or research studies evaluating new drugs. For many people, precision oncology is not about finding a single “perfect” treatment, but about narrowing choices using the best available evidence.

Doctors do not rely on biomarker findings alone. Treatment recommendations also depend on the type and stage of cancer, overall health, previous therapies, possible side effects, patient preferences, and treatment goals. Precision oncology works best when molecular information is integrated with the whole clinical picture.

Which Cancers Commonly Use Precision Oncology?

Precision oncology is used most often in cancers where specific biomarkers have already been linked to treatment decisions. This includes many cases of lung cancer, breast cancer, colorectal cancer, melanoma, ovarian cancer, prostate cancer, and certain blood cancers. In these diseases, molecular testing may be recommended at diagnosis, at recurrence, or when treatment stops working as expected.

For example, in some patients with lung cancer, testing for gene alterations can strongly influence the first treatment plan. In breast cancer, biomarkers such as hormone receptor status and HER2 are already standard parts of care, and additional genetic information may sometimes guide further choices. Similar precision approaches are also used in some gastrointestinal, gynecologic, and pediatric cancers.

Even so, not every tumor has a biomarker that leads directly to a targeted treatment. In some cases, testing provides useful biological information without changing the treatment plan right away. In others, the value of broad testing may be greater in advanced cancer, recurrent disease, or when clinical trial options are being explored.

As cancer research continues, the list of clinically meaningful biomarkers keeps growing. This means that recommendations can change over time. A result that was not actionable in the past may become more relevant later if a new treatment becomes available or if additional evidence emerges.

Benefits, Limitations, and Questions to Ask

Precision oncology can offer important benefits. It may help identify therapies that are more likely to work, reduce trial-and-error treatment decisions, and support a more personalized plan. For some patients, it also opens the door to clinical trials or newer therapies not considered on the basis of tumor location alone.

However, there are limitations. Not all cancers have known actionable biomarkers, and not all detected mutations can be treated with approved medicines. Some results are complex or uncertain, and tumors can change over time. A single biopsy may not capture every part of a cancer, especially if it has spread. In addition, access to testing and treatment can vary by region and healthcare system.

Patients often find it helpful to ask clear questions, such as what test is being ordered, what it can and cannot show, whether enough tissue is available, and how the result might change treatment. It is also reasonable to ask whether re-testing may be needed later, especially if the cancer progresses or returns. These conversations can make the process feel more understandable and collaborative.

Many cancer centers review complex biomarker findings in multidisciplinary meetings or molecular tumor boards. This allows oncologists, pathologists, geneticists, radiologists, and other specialists to interpret results together. Near the end of care planning, some patients may also seek evaluation at centers such as Acibadem International, where multidisciplinary specialists in JCI-accredited hospitals diagnose and treat cancer for international patients.

When to Discuss Biomarker Testing With a Doctor

Biomarker testing is worth discussing soon after a cancer diagnosis, especially if the cancer type commonly uses molecular information to guide treatment. It may also be appropriate when cancer returns, spreads, or no longer responds to therapy. In these settings, new testing can sometimes reveal changes that affect the next treatment step.

Patients should also bring up family history, because some biomarker findings may suggest an inherited cancer risk. This does not mean every tumor mutation is hereditary, but certain results may lead doctors to recommend genetic counseling. Understanding the difference between an inherited mutation and a tumor-only mutation is an important part of safe, accurate care.

Medical attention should not be delayed while searching for information online. The best next step is usually a conversation with an oncologist who can explain whether testing is recommended, which type is most useful, and how the findings fit into the overall treatment plan. Patients who want a second opinion may also benefit from review at a specialized cancer center.

If biopsy planning is needed, doctors may recommend a biopsy or another diagnostic procedure to obtain enough tissue for accurate analysis. The timing and choice of test are individualized, and decisions are made with the patient’s goals, safety, and overall health in mind.

Frequently asked questions

What is precision oncology in simple terms?

Precision oncology is a way of treating cancer based on the specific biological features of a person’s tumor. Doctors use biomarker and molecular test results to help choose treatments that may be more suitable for that individual cancer.

Are biomarkers the same as genetic testing?

Not exactly. Biomarker testing in cancer often looks at changes inside the tumor itself, while genetic testing can also refer to inherited changes passed through families. Sometimes both types of testing are relevant, but they answer different medical questions.

Does every person with cancer need biomarker testing?

No. Biomarker testing is very important in some cancers and less useful in others. Whether it is recommended depends on the cancer type, stage, available treatments, and whether the result is likely to change management.

Can a blood test replace a tumor biopsy?

A blood-based liquid biopsy can be helpful in certain situations, but it does not replace tissue biopsy in every case. Tissue samples often provide more complete information, especially when confirming the diagnosis and analyzing tumor structure.

What happens if no actionable biomarker is found?

A lack of actionable biomarkers does not mean there are no treatment options. Standard treatments such as surgery, chemotherapy, radiation therapy, hormone therapy, or immunotherapy may still be appropriate. The result still gives doctors useful information about how to plan care.

Can biomarker results change over time?

Yes. Tumors can evolve, especially after treatment or when the cancer progresses. That is why some patients may need repeat testing later in their cancer journey.

References

• National Cancer Institute
• American Society of Clinical Oncology
• World Health Organization
• European Society for Medical Oncology
• National Comprehensive Cancer Network

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.